Larry J. Dumont
Dartmouth College
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Larry J. Dumont.
Transfusion | 2008
Larry J. Dumont; James P. AuBuchon
BACKGROUND: FDA requirements for recovery of radiolabeled red blood cells (RBCs) 24 hours after autologous reinfusion in normal subjects have evolved over time. This study defined the ability of currently available RBC systems to satisfy the most recently proposed criteria.
Transfusion | 2002
Larry J. Dumont; James P. AuBuchon; Pamela Whitley; Louise Herschel; Adrienne Johnson; Deanna McNeil; Sherrie Sawyer; Jill Roger
BACKGROUND: Bacterial screening may effectively reduce the morbidity and mortality risk associated with extended storage of platelets. Platelet viability then becomes the primary determinant of acceptable storage time. This study evaluates the effectiveness of platelets stored in plasma for 7 days.
Transfusion | 1996
Larry J. Dumont; Walter H. Dzik; Paolo Rebulla; Harvey Brandwein
Background: The increased use of white (WBC)‐reduced blood components has prompted many institutions to develop quality assurance programs directed to such component preparation processes. For consistent preparation of WBC‐reduced blood components that meet clinical needs as well as national standards, a program of process validation and control should be instituted. This involves controlling key factors that affect WBC reduction as well as periodic monitoring of the residual cellular content of components. Practical guidelines for the implementation of such a program are provided.
Vox Sanguinis | 2004
Tania VandenBroeke; Larry J. Dumont; S. Hunter; Janice Nixon; Scott Murphy; J. Roger; Louise Herschel; James P. AuBuchon; Hans Gulliksson; T. Dengler; V. Hornsey; Chris Prowse
Background and Objectives Extent of shape change (ESC) and hypotonic shock response (HSR) have been widely used to characterize the in vitro function of platelets and have been shown to correlate with in vivo viability. These assays have been routinely performed using platelet‐poor plasma (PPP) as the test sample diluent. Because of the increasing popularity of storing platelets in synthetic media, it is important to understand the effects of using these synthetic media as test diluents for ESC and HSR measurements. The objective of this study was to determine the effect of using platelet storage solutions vs. plasma for the in vitro testing of ESC and HSR.
Transfusion | 2010
Larry J. Dumont; Steven H. Kleinman; Murphy; Rebecca Lippincott; Robert Schuyler; Jaime Houghton; Peyton S. Metzel
BACKGROUND: The PASSPORT study was an FDA‐mandated surveillance of outdated 7‐day apheresis platelets (APs) to assess the bacterial culture release test (RT) performance and the chance of transfusing APs containing viable bacteria compared to untested 5‐day APs.
Transfusion | 2010
Larry J. Dumont; Steven H. Kleinman; James R. Murphy; Rebecca Lippincott; Robert Schuyler; Jaime Houghton; Peyton S. Metzel
BACKGROUND: The PASSPORT study was an FDA‐mandated surveillance of outdated 7‐day apheresis platelets (APs) to assess the bacterial culture release test (RT) performance and the chance of transfusing APs containing viable bacteria compared to untested 5‐day APs.
Transfusion | 2008
Nancy M. Heddle; Donald M. Arnold; Diana Boye; Kathryn E. Webert; Ilona Resz; Larry J. Dumont
BACKGROUND: A systematic review and meta‐analysis was performed to determine if there were differences between apheresis platelet concentrates (APCs) or platelets (PLTs) derived from whole blood (WBD) for the outcomes acute reactions, alloimmunization, refractoriness, corrected count increment (CCI), radiolabeled recovery and survival, time to next transfusion, and bleeding.
Transfusion | 2008
Tatsuro Yoshida; James P. AuBuchon; Larry J. Dumont; James D. Gorham; Sean C. Gifford; Kevin Y. Foster; Mark W. Bitensky
BACKGROUND: Red cell (RBC) storage can be extended to 9 weeks under anaerobic or alkaline conditions. Simultaneous use of these approaches has not provided additive benefit. Our objective was to determine whether anaerobic storage with acidified additive solution (AS) coupled with metabolic rejuvenation might further improve the benefits of anaerobic storage.
Transfusion Medicine Reviews | 2014
John D. Roback; Cassandra D. Josephson; Edmund K. Waller; James L. Newman; Sulaiman Karatela; Karan Uppal; Dean P. Jones; James C. Zimring; Larry J. Dumont
Population-based investigations suggest that red blood cells (RBCs) are therapeutically effective when collected, processed, and stored for up to 42 days under validated conditions before transfusion. However, some retrospective clinical studies have shown worse patient outcomes when transfused RBCs have been stored for the longest times. Furthermore, studies of RBC persistence in the circulation after transfusion have suggested that considerable donor-to-donor variability exists and may affect transfusion efficacy. To understand the limitations of current blood storage technologies and to develop approaches to improve RBC storage and transfusion efficacy, we investigated the global metabolic alterations that occur when RBCs are stored in AS-1 (AS1-RBC). Leukoreduced AS1-RBC units prepared from 9 volunteer research donors (12 total donated units) were serially sampled for metabolomics analysis over 42 days of refrigerated storage. Samples were tested by gas chromatography/mass spectrometry and liquid chromatography/tandem mass spectrometry, and specific biochemical compounds were identified by comparison to a library of purified standards. Over 3 experiments, 185 to 264 defined metabolites were quantified in stored RBC samples. Kinetic changes in these biochemicals confirmed known alterations in glycolysis and other pathways previously identified in RBCs stored in saline, adenine, glucose and mannitol solution (SAGM-RBC). Furthermore, we identified additional alterations not previously seen in SAGM-RBCs (eg, stable pentose phosphate pathway flux, progressive decreases in oxidized glutathione), and we delineated changes occurring in other metabolic pathways not previously studied (eg, S-adenosyl methionine cycle). These data are presented in the context of a detailed comparison with previous studies of SAGM-RBCs from human donors and murine AS1-RBCs. Global metabolic profiling of AS1-RBCs revealed a number of biochemical alterations in stored blood that may affect RBC viability during storage as well as therapeutic effectiveness of stored RBCs in transfusion recipients. These results provide future opportunities to more clearly pinpoint the metabolic defects during RBC storage, to identify biomarkers for donor screening and prerelease RBC testing, and to develop improved RBC storage solutions and methodologies.
Transfusion | 2006
Larry J. Dumont; James P. AuBuchon; Hans Gulliksson; Sherrill J. Slichter; M. Dean Elfath; Stein Holme; James R. Murphy; Leslie Rose; Mark A. Popovsky; Scott Murphy
BACKGROUND: The pH environment of stored platelet (PLT) products is recognized as an important factor and is generally used as a key surrogate measure of PLT viability. It is the only in vitro measurement that has been translated into industry standards and regulatory rules or specifications for storage of PLT products. The objective of this study was to evaluate the effect of in vitro pH on the in vivo recovery and survival of autologous PLT products.